Key Stats for Caris Life Sciences Stock
- Current Price: $20.00
- Target Price (Mid): ~$48
- Street Target: ~$27
- Potential Total Return: ~140%
- Annualized IRR: ~22% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Caris Life Sciences (CAI) reported a record second quarter after the close on August 5, and the next day shares jumped 21.58% to close at $20.00, the sharpest earnings reaction since the company went public. The print beat the Street’s revenue estimate by nearly 11% and pushed management to raise full-year guidance. Investors who searched why the stock spiked got a fast answer: the numbers came in far better than a market that had spent the summer selling had priced in.
Even after that pop, shares still sit roughly 53% below their 52-week high of $42.50. The stock had fallen as much as 62.98% to a low of $14.19 on May 15 before this print began the repair. So the live tension is not whether the quarter was good. It plainly was. It is whether one strong report resets a stock the market had nearly halved, or simply recovers a fraction of the damage.
The Capacity Bet Management Left Out of Guidance
The headline was the guidance raise, to a range of $1.03 billion to $1.04 billion, implying 27% to 28% growth. The more revealing detail is what that raise assumes: essentially nothing from Caris Detect, the multi-cancer early detection blood test launched in June. CFO Luke Power said the outlook runs entirely on the existing molecular profiling business, because management wants a quarter or two of history before crediting Detect with revenue. It is self-pay for now, with no reimbursement assumed.
Yet management is building lab capacity for it at a scale that dwarfs the current business. Founder and CEO David Dean Halbert put it plainly on the call: “Our current capacity is about $1 billion a year of revenue, and we’re just about to triple that. So that will be about $3 billion a year in revenue, and we’re still worried about back orders.” That is a team constructing a footprint for a product it refuses to put in guidance, because demand from concierge medicine, longevity clinics, and digital partners like Everlywell has outrun the rollout. A national direct-to-consumer ad campaign was set to begin filming the Monday after the call and run within a couple of months.
The reason the market cares is the validation behind the test. Detect identifies 58 cancer types from one blood draw and, in the company’s study, resolves 83.9% of true positives in a single diagnostic workup, an average of 1.19 procedures per patient. Halbert’s pitch is a direct challenge to single-cancer screening: why settle for a test that looks for one cancer when one draw can look for many and still catch disease at Stage 1, where cure rates run near 90%.
See historical and forward estimates for Caris Life Sciences stock (It’s free!) >>>
A Beat That Landed Into a Skeptical Street
Revenue rose 45% year-over-year to $263.71 million, ahead of the $238.08 million consensus by 10.77%. Molecular profiling services grew 55% to $252.3 million, GAAP gross margin expanded to 68% from 63% a year earlier, and adjusted EBITDA reached $55.7 million against a $32.98 million estimate, more than tripling from $16.7 million a year ago. It was a fifth straight quarter of positive adjusted EBITDA and free cash flow, and the GAAP net loss narrowed to $0.6 million even after a one-time $25 million charge to refinance a term loan. The volume line mattered most: roughly 59,200 clinical cases, up 18% year-over-year and a record 6,400 sequential additions, which directly rebuts the fear that drove the summer selloff, that a January sales-force realignment had broken the growth engine. Power said the reorganized field team crossed 300 sellers in July.
That beat landed into a sell side that had been trimming. Ahead of the print, BofA cut its target to $23, Evercore ISI to $25, and TD Cowen to $30, each keeping a Buy-equivalent rating as part of routine diagnostics-group previews. When actuals came in double digits ahead of consensus, the re-rating was violent. On valuation, the stock trades around 4.75 times next-twelve-month enterprise value to revenue, below the peer mean near 11.6 times and names like Natera at 12.1 times and GRAIL at 10.4 times. The bull reads that as a mispricing on a platform crossing into durable profitability. The bear notes marginal net profitability, a 70 times NTM P/E ratio that says little on thin earnings, and Q3 EBITDA management guided down to $10 million to $16 million as spending ramps. The discount is real, and so is the reason for it.
See how Caris Life Sciences performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $20.00
- Target Price (Mid): ~$48
- Potential Total Return: ~140%
- Annualized IRR: ~22% / year
See analysts’ growth forecasts and price targets for Caris Life Sciences stock (It’s free!) >>>
Using the mid-case scenario realized at the end of 2030, TIKR’s model puts a fair value near $48, about 140% total return over roughly 4.4 years, or around 22% annualized. The two revenue drivers are clinical case volume, now compounding again after the reorg, and continued average selling price gains as MI Cancer Seek and newer assays like ChromoSeq layer in higher-reimbursed tests. The margin driver is the operating leverage already visible in a 68% gross margin and adjusted EBITDA that more than tripled year-over-year. The primary risk is that Caris Detect, the platform’s largest source of optionality, is self-pay with no reimbursement path assumed and no revenue in guidance, so a slow conversion of demand into paid volume leaves the model leaning on the core business alone. Upside: Detect scales toward its tripled capacity and the market re-rates a profitable screening platform. Downside: screening economics disappoint and the stock re-couples to its still-modest earnings base.
Conclusion
Watch Q3 clinical volume, which management guided to roughly 20% growth in the 61,000 to 62,000 case range, with the report expected in early November based on prior cadence. Hit or beat it, and the argument that the reorg permanently damaged growth is finished. Miss it, and this quarter looks like a bounce rather than a turn. The wilder card sits off the guidance entirely: the first quarter Caris actually books Detect revenue will show whether a $3 billion capacity bet was foresight or overreach.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Caris Life Sciences?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Caris Life Sciences, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Caris Life Sciences alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Caris Life Sciences on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
